# A Study of ADR-001 in Patients With Liver Cirrhosis

> **NCT03254758** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rohto Pharmaceutical Co., Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Decompensated Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cell

## Key facts

- **NCT ID:** NCT03254758
- **Lead sponsor:** Rohto Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2023-04-13
- **Final completion:** 2023-04-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254758, "A Study of ADR-001 in Patients With Liver Cirrhosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03254758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*